Effectiveness of Dupilumab in the Treatment of Patients with Uncontrolled Severe CRSwNP: A “Real-Life” Observational Study in Naïve and Post-Surgical Patients
Authors:
- Giancarlo OttavianoGOGiancarlo Ottaviano
- Tommaso SaccardoTSTommaso Saccardo
- Giuseppe RoccuzzoGRGiuseppe Roccuzzo
- Riccardo BernardiRBRiccardo Bernardi
- Alessandra Di ChiccoACAlessandra Di Chicco
- Alfonso Luca PendolinoAPAlfonso Luca Pendolino
- Bruno ScarpaBSBruno Scarpa
- Edoardo MairaniEMEdoardo Mairani
- Piero NicolaiPNPiero Nicolai
Open Access
- 17 September 2022
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (9) , 1526
Abstract
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) represents 25–30% of all CRS cases, and in the most severe forms it is associated with a poor quality of life and a high rate of nasal polyps’ recurrence after surgery. Dupilumab has been suggested as a treatment option for severe CRSwNP. Methods: Patients with severe CRSwNP receiving dupilumab from January 2021 were followed up at 1, 3, 6, 9 and 12 months from the first administration and were considered for this study. At baseline and at each follow-up, patients underwent nasal endoscopy and completed the Sinonasal Outcome Test (SNOT)-22, a Visual Analogue Scale (VAS) for smell/nasal obstruction, the Nasal Congestion Score and the Asthma Control Test. Peak nasal inspiratory flow (PNIF), a smell test, nasal cytology and blood eosinophilia were also evaluated. Results: Forty-seven patients were included in the study. Of these, 33 patients had a history of previous surgery (ESS) and had recurrent nasal polyps, while 14 patients were naïve to nasal surgery. Both subjective and objective parameters improved after biological treatment and were correlated with each other (p < 0.05), except for the SNOT-22 and the nasal polyp’s score. No correlations were found between nasal and blood eosinophilia. No differences were observed when comparing the post-surgical and the naïve groups. Conclusions: Dupilumab improves nasal obstruction and the sense of smell and reduces the level of local inflammation in severe CRSwNP patients in a similar way in both naïve and post-surgical patients.Keywords
This publication has 31 references indexed in Scilit:
- Chronic Rhinosinusitis—Could Phenotyping or Endotyping Aid Therapy?American Journal of Rhinology & Allergy, 2018
- Comparison between unilateral PNIF and rhinomanometry in the evaluation of nasal cycleRhinology journal, 2018
- Endoglin (CD105) expression in sinonasal polyposisEuropean Archives of Oto-Rhino-Laryngology, 2015
- Comparison between unilateral PNIF and rhinomanometry in healthy and obstructed nosesRhinology journal, 2014
- Olfactory Sensitivity and Sexual Desire in Young Adult and Elderly Men: An Introductory InvestigationAmerican Journal of Rhinology & Allergy, 2013
- Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthmaJournal of Allergy and Clinical Immunology, 2013
- Smoking and chronic rhinitis: effects of nasal irrigations with sulfurous-arsenical-ferruginous thermal waterAmerican Journal of Otolaryngology, 2012
- Omalizumab Is Effective In Allergic And Non-allergic Patients With Nasal Polyps And AsthmaJournal of Allergy and Clinical Immunology, 2012
- Nasal functional modifications after physical exercise: olfactory threshold and peak nasal inspiratory flowRhinology journal, 2010
- Do corticosteroids induce apoptosis in nasal polyp inflammatory cells? in vivo and in vitro studiesThe Laryngoscope, 1999